Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study
© Guo et al.; licensee BioMed Central Ltd. 2013
Received: 18 September 2012
Accepted: 11 March 2013
Published: 21 March 2013
Open Peer Review reports
Pre-publication versions of this article and author comments to reviewers are available by contacting email@example.com.
|18 Sep 2012||Submitted||Original manuscript|
|Resubmission - Version 2|
|Submitted||Manuscript version 2|
|26 Sep 2012||Author responded||Author comments - Jun Guo|
|Resubmission - Version 3|
|26 Sep 2012||Submitted||Manuscript version 3|
|26 Nov 2012||Reviewed||Reviewer Report - Brian Rini|
|10 Dec 2012||Reviewed||Reviewer Report - Ronald Bukowski|
|18 Jan 2013||Author responded||Author comments - Jun Guo|
|Resubmission - Version 4|
|18 Jan 2013||Submitted||Manuscript version 4|
|11 Mar 2013||Editorially accepted|
|21 Mar 2013||Article published||10.1186/1471-2407-13-136|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting firstname.lastname@example.org. All previous versions of the manuscript and all author responses to the reviewers are also available.
You can find further information about the peer review system here.